13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04225312
(ClinicalTrials.gov)
February 3, 20203/1/2020Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple SclerosisPersonalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: Personalized extended interval dosing of natalizumab;Drug: Standard interval dosingVU University Medical CenterStichting MS Research;Innovatiefonds ZorgverzekeraardRecruiting18 YearsN/AAll300Phase 4Netherlands
2EUCTR2019-002566-13-NL
(EUCTR)
19/12/201929/10/2019Personalizing the treatment with natalizumab in patients with multiple sclerosisPersonalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis - NEXT-MS Relapsing remitting multiple sclerosis
MedDRA version: 20.1;Level: LLT;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Amsterdam University Medical CenterNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
300Phase 4Netherlands